Purpose: To report the successful use of tofacitinib in the treatment of refractory uveitis and scleritis. Observations: Two patients, one with scleritis and another with anterior and intermediate uveitis, presented with refractory disease after failure of multiple steroid-sparing therapies. Treatment with tofacitinib led to durable resolution of uveitis and scleritis. Conclusions and importance: Tofacitinib is a potential novel treatment option for refractory, noninfectious inflammatory eye disease.

Original languageEnglish
Pages (from-to)53-55
Number of pages3
JournalAmerican Journal of Ophthalmology Case Reports
StatePublished - Mar 2019


  • JAK
  • STAT
  • Scleritis
  • Tofacitinib
  • Uveitis


Dive into the research topics of 'Tofacitinib for refractory uveitis and scleritis'. Together they form a unique fingerprint.

Cite this